Suppr超能文献

英夫利昔单抗挽救治疗合并艰难梭菌感染的急性重症溃疡性结肠炎:病例系列报道

Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series.

作者信息

Markovic Srdjan, Jankovic Marijana, Kalaba Ana, Zogovic Branimir, Sreckovic Slobodan S

机构信息

Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", Belgrade, SRB.

Department of General Surgery, Royal Prince Alfred Hospital, New South Wales, AUS.

出版信息

Cureus. 2021 Oct 25;13(10):e19019. doi: 10.7759/cureus.19019. eCollection 2021 Oct.

Abstract

Relapses in inflammatory bowel disease (IBD) complicated by  infection (CDI) are associated with significant morbidity and mortality. CDI can exacerbate the course of IBD and may result in prolonged hospitalizations, admissions to intensive care, surgical interventions, or even death. Early detection and aggressive treatment with systemic corticosteroids or biologics such as infliximab are often needed in severe presentations. Five cases of relapsed ulcerative colitis complicated by fulminant CDI were retrospectively reviewed. Biological therapy with infliximab was initiated upon multidisciplinary team assessment as the cases were resistant to standard IBD therapy. All five patients improved clinically and avoided early surgical intervention. Some required prolonged therapy with infliximab to achieve remission. Early recognition of CDI and aggressive therapy with biologics may be required to avoid complications in the IBD patients experiencing a relapse. Infliximab therapy should be considered early on, especially where the disease is resistant to standard therapy.

摘要

炎症性肠病(IBD)合并艰难梭菌感染(CDI)后的复发与显著的发病率和死亡率相关。CDI可使IBD病情恶化,并可能导致住院时间延长、入住重症监护病房、接受手术干预,甚至死亡。在严重病例中,通常需要早期检测并用全身性皮质类固醇或生物制剂(如英夫利昔单抗)进行积极治疗。回顾性分析了5例复发性溃疡性结肠炎合并暴发性CDI的病例。由于这些病例对标准IBD治疗耐药,经多学科团队评估后启动了英夫利昔单抗生物治疗。所有5例患者临床症状均有改善,避免了早期手术干预。部分患者需要长期使用英夫利昔单抗治疗以实现缓解。对于复发的IBD患者,可能需要早期识别CDI并用生物制剂进行积极治疗以避免并发症。应尽早考虑使用英夫利昔单抗治疗,尤其是在疾病对标准治疗耐药的情况下。

相似文献

10
Management of inflammatory bowel disease with infection.炎症性肠病合并感染的管理
World J Gastroenterol. 2017 Jul 21;23(27):4986-5003. doi: 10.3748/wjg.v23.i27.4986.

本文引用的文献

3
in Inflammatory Bowel Disease: A Retrospective Study.《炎症性肠病:一项回顾性研究》
Gastroenterol Res Pract. 2017;2017:4803262. doi: 10.1155/2017/4803262. Epub 2017 Oct 4.
8
Is fidaxomicin worth the cost? An economic analysis. fidaxomicin 的成本效益如何?一项经济分析。
Clin Infect Dis. 2013 Aug;57(4):555-61. doi: 10.1093/cid/cit346. Epub 2013 May 23.
9
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.艰难梭菌感染的诊断、治疗和预防指南。
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验